Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Börjesson, Pontus K E ^a   Postema, Ernst J ^b   Roos, Jan C ^a   Colnot, David R ^a   Marres, Henri A M ^b   Van Schie, Mathijs H ^c   Stehle, Gerd ^c   De Bree, Remco ^a   Snow, Gordon B ^a   Oyen, Wim J G ^b   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIVATUZUMAB; BLEOMYCIN; CD44V6 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BIWA4; RHENIUM 186; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW; BONE MARROW TOXICITY; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GOUT; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HUMAN; IMAGE ANALYSIS; IMMUNOGENICITY; ISOTOPE LABELING; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; PETECHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THRUSH; TUMOR CELL; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN STRUCTURE, TERTIARY; QUALITY CONTROL; RADIOISOTOPES; RADIOMETRY; RHENIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 10844290511     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94: 153-156, 2001.
2. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
3. Dennington, M. L., Carter, D. R., and Meyers, A. D. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope, 90: 196-201, 1980.
4. Zbaren, P., and Lehmann, W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch. Otolaryngol. Head Neck Surg., 113: 762-764, 1987.
5. Nishijima, W., Takooda, S., Tokita, N., Takayama, S., and Sakura, M. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch. Otolaryngol. Head Neck Surg., 119: 65-68, 1993.
6. Leemans, C. R., Tiwari, R., Nauta, J. J., Van der Waal, I., and Snow, G. B. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer (Phila.), 73: 187-190, 1994.
7. Leemans, C. R., Tiwari, R., Nauta, J. J., Van der Waal, I., and Snow, G. B. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer (Phila.), 71: 452-456, 1993.
8. Postema, E. J., Boerman, O. C., Oyen, W. J., Raemaekers, J. M., and Corstens, F. H. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur. J. Nucl. Med., 28: 1725-1735, 2001.
9. Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., Silverman, D. H., Parker, E., and Grillo-Lopez, A. J. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 17: 3793-3803, 1999.
10. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., and White, C. A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refactor low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 20: 2453-2463, 2002.
11. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259-1266, 2000.
12. 131I-BI (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
13. Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., Bush, S. A., Durack, L. D., Martin, P. J., Fisher, D. R., Wood, B., Borrow, J. W., Porter, B., Smith, J. P., Matthews, D. C., Appelbaum, F. R., and Bernstein, I. D. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 96: 2934-2942, 2000.
14. Heider, K. H., Sproll, M., Susani, S., Patzelt, E., Beaumier, P., Ostermann, E., Ahorn, H., and Adolf, G. R. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother., 43: 245-253, 1996.
15. Schrijvers, A. H., Quak, J. J., Uyterlinde, A. M., Van Walsum, M., Meijer, C. J., Snow, G. B., and Van Dongen, G. A. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res., 53: 4383-4390, 1993.
16. Verel, I., Heider, K. H., Siegmund, M., Ostermann, E., Patzelt, E., Sproll, M., Snow, G. B., Adolf, G. R., and Van Dongen, G. A. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44v6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer, 99: 396-402, 2002.
17. Kugelman, L. C., Ganguly, S., Haggerty, J. G., Weissman, S. M., and Milstone, L. M. The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J. Investig. Dermatol., 99: 886-891, 1992.
18. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer Res., 1: 591-598, 1995.
19. 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res., 6: 3046-3055, 2000.
20. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med., 41: 1999-2010, 2000.
21. 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a Phase I dose escalation study. Clin. Cancer Res., 8: 3401-3406, 2002,
22. Kramer, E. L., Liebes, L., Wasserheit, C., Noz, M. E., Blank, E. W., Zabalegui, A., Melamed, J., Furmanski, P., Peterson, J. A., and Ceriani, R. L. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin. Cancer Res., 4: 1679-1688, 1998.
23. Caron, P. C., Jurcic, J. G., Scott, A. M., Finn, R. D., Divgi, C. R., Graham M. C., Jureidini, I. M., Sgouros, G., Tyson, D., and Old, L. J. A Phase I B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
24. Heider, K. H., Mulder, J. W., Ostermann, E., Susani, S., Patzelt, E., Pals, S. T., and Adolf, G. R. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur. J. Cancer, 31A: 2385-2391, 1995.
25. Himmler, A., Maurer-Fogy, I., Kronke, M., Scheurich, P., Pfizenmaier, K., Lantz, M., Olsson, I., Hauptmann, R., Stratowa, C., and Adolf, G. R. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol., 9: 705-715, 1990.
26. 186Re using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J. Nucl. Med., 34: 1953-1963, 1993.
27. 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. J. Immunol. Immunother., 52: 576-582, 2003.
28. Shen, S., DeNardo, G. L., Sgouros, G., O'Donnell, R. T., and DeNardo, S. J. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J. Nucl. Med., 40: 2102-2106, 1999.
29. Caron, P. C., Schwartz, M. A., Co, M. S., Queen, C., Finn, R. D., Graham, M. C., Divgi, C. R., Larson, S. M., and Scheinberg, D. A. Murine and humanized constructs of monoclonal antibody M 195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer (Phila.), 73: 1049-1056, 1994.
30. Kramer, E. L., DeNardo, S. J., Liebes, L., Kroger, L. A., Noz, M. E., Mizrachi, H., Salako, Q. A., Furmanski, P., Glenn, S. D., DeNardo, G. L., and Ceriani, R. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study. J. Nucl. Med., 34: 1067-1074, 1993.
31. DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., Noz, M., Glenn, S. D., Ceriani, R. L., and DeNardo, G. L. Radioimmunotherapy for breast cancer using indium111/yttrium-90 BrE-3: results of a Phase I clinical trial. J. Nucl. Med., 38: 1180-1185, 1997.
32. Ritter, G., Cohen, L. S., Williams, C., Jr., Richards, E. C., Old, L. J., and Welt, S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res., 61: 6851-6859, 2001.
33. Welt, S., Divgi, C. R., Kemeny, N., Finn, R. D., Scott, A. M., Graham, M., Germain, J. S., Richards, E. C., Larson, S. M., Oettgen, H. F., and Old, L. J. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12: 1561-1571, 1994.
34. De Bree, R., Kuik, D. J., Quak, J. J., Roos, J. C., Van den Brekel, M. W., Castelijns, J. A., van Wagtendonk, F. W., Greuter, H., Snow, G. B., and Van Dongen, G. A. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur. J. Nucl. Med., 25: 1562-1565, 1998.